Advanced search
Publication Cover
Drug and Alcohol Review Volume 19, 2000 - Issue 1
Journal homepage
21
Views
8
CrossRef citations to date
0
Altmetric
Research Article

Naltrexone in the treatment of heroin dependence: a literature review

Thamizan K. Tucker, Alison J. Ritter Turning Point Alcohol and Drug Centre Inc., Fitzroy, Australia
Pages 73-82 | Published online: 12 Jul 2009

  • O'Malley SS. Opioid antagonists in the treatment of alcohol dependence: clinical efficacy and prevention of relapse. Alcohol Alcohol 1996;31:77-81.
  • O'Brien CP, Volcipelli LA, Volcipelli JR. Naltrexone in the treatment of alcoholism: a clinical review. Alcohol 1996;13:35-9.
  • DuPont Pharmaceuticals. REVIA: product monograph. USA: DuPont Pharmaceuticals, 1995.
  • Gonzalez JP, Brogden RN. Naltrexone: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of opioid dependence. Drugs 1988;35:192-213.
  • Atkinson RL, Berke LK, Drake CR, et al. Effects of long-term therapy with naltrexone on body weight in obesity. Clin Pharm Ther 1985;38 :419-22.
  • Garcia-Alonso F, GutierrezM, San L, et al. A multicentre study to introduce naltrexone for opiate dependence in Spain. Drug Alcohol Depend 1989;23:117-21.
  • Greenstein RA, Arndt IC, McLellan AT, O'Brien CP, Evans B. Naltrexone: a clinical perspective. J Clin Psychiatry 1984;45 :25-8.
  • Hcluster LE, Johnson K, Boukhabza D, Gillespie HK. Aversive effects of naltrexone in participants not dependent on opiates. Drug Alcohol Depend 1981;8:37-41.
  • Ling W, Wesson DR. Naltrexone treatment for addicted health-care professionals: a collaborative private practice experience. J Clin Psychiatry 1984;45:46-8.
  • Resnick RB, Washton AM, Thomas MA, Kestenbaum RS. Naltrexone in the treatment of opiate dependence. In: Petersen RC, ed. The international challenge of drug abuse, vol. 19. NIDA research monograph series. Rockville, MD: US Department of Health, Education, and Welfare, 1978:321-32.
  • Tennant FS, Rawson RA, Cohen MA, Mann A. Clinical experience with naltrexone in suburban opioid addicts. J Clin Psychiatry 1984;45:42-5.
  • Wodak A, Latt N. Naltrexone. Drugs in Society 1995;1:26-7.
  • O'Brien CP. A new approach to the management of opioid dependence: naltrexone, an oral antagonist. J Clin Psychiatry 1984;45:1-59.
  • Julius DA. Historical trends in naltrexone research. In: Petersen RC, ed. The international challenge of drug abuse, vol. 19. NIDA research monograph series. Rockville, MD: US Department of Health, Education, and Welfare, 1978:301-7.
  • Kleber HD. Naltrexone. J Subst Abuse Treat 1985;2:117-22.
  • O'Brien C, Childress A, McLellar A, Ternes J, Ehrman R. Use of naltrexone to extinguish opioidconditioned responses. J Clin Psychiatry 1984;45:53-6.
  • O'Brien CP, Greenstein R, Woody GE. Update on naltrexone treatment. In: Petersen RC, ed. The international challenge of drug abuse, vol. 19. NIDA research monograph series. Rockville, MD: Department of Health, Education and Welfare, 1978:315-20.
  • Schecter A. The role of narcotic antagonists in the rehabilitation of opiate addicts: a review of naltrexone. Am J Drug Alcohol Abuse 1980;7:1-18.
  • O'Brien CP. Recent developments in the pharmacotherapy of substance abuse. J Consult Clin Psychol 1996;64:677-86.
  • Fram DH, Marmo J, Holden R. Naltrexone treatment: the problem of patient acceptance. J Subst Abuse Treat 1989;6:119-22.
  • Lewis DC, Mayer J, Hersch RG, Black R. Narcotic antagonist treatment: clinical experience with naltrexone. Int J Addict 1978;13:961-73.
  • Singleton EG, Sherman MF, Bigelow GE. The index of choice: indications of methadone patients selection of naltrexone treatment. Am J Drug Alcohol Abuse 1984;10:209-21.
  • National Research Council Committee on Clinical Evaluation of Narcotic Antagonists. Clinical evaluation of naltrexone treatment of opiate-dependent individuals. Report of the National Research Council Committee on clinical evaluation of narcotic antagonists. Arch Gen Psychiatry 1978;35:335-40.
  • O'Brien CP, Greenstein RA, Mintz J, Woody GE. Clinical experience with naltrexone. Am J Drug Alcohol Abuse 1975;2:365-77.
  • Thomas M, Kauders F, Harris M, Cooperstein J, Hough G, Resnick R. Clinical experiences with naltrexone in 370 detoxified addicts. In: Julius D, Renault P, eds. Narcotic antagonists: naltrexone, vol. 9. NIDA research monograph series. Rockville, MD: National Institute on Drug Abuse, 1976:88-92.
  • Greenstein R, O'Brien C, Mintz J, Woody G, Hanna N. Clinical experience with naltrexone in a behavioural research study: an interim report. In: Julius D, Renault P, eds. Narcotic antagonists: naltrexone, vol. 9. NIDA research monograph series. Rockville, MD: National Institute on Drug Abuse, 1976.
  • Hcluster LE, Schwin RL, Kasper P. Naltrexone treatment of opiate-dependent persons. Drug Alcohol Depend 1977;2:203-9.
  • Schifano E, Marra R. Naltrexone for heroin addiction: encouraging results from Italy. Int J Clin Pharmacol Therapy Toxicol 1990;28 :144-146.
  • Shufman EN, Porat S, Witztum E, Gandacu D, BarHamburger R, Ginath Y. The efficacy of naltrexone in preventing reabuse of heroin after detoxification. Biol Psychiatry 1994;35 :931-41.
  • Brahen LS, Henderson RK, Capone T, Kordal N. Naltrexone treatment in a jail work-release program. J Clin Psychiatry 1984;45:49-52.
  • Washton AM, Po t ta s h AC, Gold MS. Naltrexone in addicted business executives and physicians. J Clin Psychiatry 1984)45:39-41.
  • Capone T, Brahen L, Condren R, Kordel N, Melchionda R, Peterson M. Retention and outcome in a narcotic antagonist treatment program. J Clin Psychology 1986;42:825-33.
  • Gutiérrez M, Ballesteros J, Gonzalez Oliveros R, de Apodaka JR. Retention rates in two naltrexone programmes for heroin addicts in Vitoria, Spain. Eur Psychiatry 1995;10 :1 83-8.
  • Lerner A, Sigal M, Bacalu A, Shiff R, Burganski I, Gelkopf M. A naltrexone double blind placebo controlled study in Israel. Israel J Psychiatr Rel Sci 1992;29:36-43.
  • San L, Pomarol G, Peri JM, Olle JM, Cami J. Follow-up after a six-month maintenance period on naltrexone versus placebo in heroin addicts. Br J Addict 1991;86:983-990.
  • Cornish JW, Metzger D, Woody GE, et al. Naltrexone pharmacotherapy for opioid dependent federal probationers. J Subst Abuse Treat 1997;14:529-34.
  • Gerra G, Marcato A, Caccavari R, et al. Clonidine and opiate receptor antagonists in the treatment of heroin addiction. J Subst Abuse Treat 1995;12:35-41.
  • Grey CC, Osborn E, Reznikoff M. Psychosocial factors in outcome in two opiate addiction treatments. J Clin Psychology 1986;42:185-9.
  • Osborn E, Grey C, Reznikoff M. Psychosocial adjustment, modality choice, and outcome in naltrexone versus methadone treatment. Am J Drug Alcohol Abuse 1986;12:383-8.
  • Greenstein RA, Evans BD, McLellan AT, O'Brien CP. Predictors of favourable outcome following naltrexone treatment, vol. 43. NIDA research monograph series. Rockville, MD: National Institute on Drug Abuse, 1982:294-301.
  • Judson B, Goldstein A. Naltrexone treatment of heroin addiction: one-year follow-up. Drug Alcohol Depend 1984;13:357-65.
  • Ling W. Naltrexone: the clinical investigator's dilemma. In: Petersen RC, ed. the international challenge of drug abuse, vol. 19. NIDA research monograph series. Rockville, MD: US Department of Health, Education, and Welfare, 1978:308-314.
  • Rounsaville BJ. Can psychotherapy rescue naltrexone treatment of opioid addiction?, vol. 150. In: Onken LS, Blaine JD, Boren JJ, eds. Integrating behavioural therapies with medications in the treatment of drug dependence. NIDA research services. Rockville, MD: National Institute on Drug Abuse, 1995:37-52.
  • Altman JL, Meyer RE, Mirin SM, McNamee HB, McDougle M. Opiate antagonists and the modification of heroin self-administration behavior in man: an experimental study. Int J Addict 1976;11:481-99.
  • Mello NK, Mendelson JH, Kuehnle JC, Sellers MS. Opérant analysis of human heroin self-administration and the effects of naltrexone. J Pharmacol Exp Ther 1981;216:45-54.
  • Judson BA, Carney TM, Goldstein A. Naltrexone treatment of heroin addiction: efficacy and safety in a double-blind dosage comparison. Drug Alcohol Depend 1981;7:235-46.
  • Resnick R, Volavka J, Freedman AM, Thomas M. Studies of EN-1639A (naltrexone): a new narcotic antagonist. Am J Psychiatry 1974;131:646-50.
  • Sideroff SI, Charuvastra VC, Jarvik ME. Craving in heroin addicts maintained on the opiate antagonist naltrexone. Am J Drug Alcohol Abuse 1978; 5:415-23.
  • Foy A, Sadler C, Taylor A. An open trial of naltrexone for opiate dependence. Drug Alcohol Rev 1998; 17:167-74.
  • Arndt I, McLellan AT, O'Brien CP. Abstinence treatments for opiate addicts: therapeutic community or naltrexone? 45th Annual Scientific Meeting of the Committee on Problems of Drug Dependence, Inc: Drug abuse treatment (1983, Lexington, KY). NIDA Research Monograph Series 1984;49:275-81.
  • Rawson R A, Washton AM, Resnick RB, Tennant FS. Clonidine hydrochloride detoxification from methadone treatment--the value of naltrexone aftercare. Adv Alcohol Subst Abuse 1984;3:41-9.
  • Rawson RA, Tennant FS. Five-year follow-up of opiate addicts with naltrexone and behavior therapy, vol. 49. National Institute on Drug Abuse Research Monograph Series. 45th Annual Scientific Meeting of the Committee on Problems of Drug Dependence, Inc: Drug abuse treatment (1983, Lexington, KY). Rockville, MD: US Department of Health and Human Services, Public Health Service, National Institutes of Health, 1984.
  • Christie MJ, Harvey AI. Pharmacological options for management of opioid dependence. Drug Alcohol Rev 1993;12:71-80.
  • psychologic and pharmacologie strategies. J Clin Psychiatry 1984;45:29-38.
  • Kleber HD, Kosten TR. Naltrexone induction: psychologic and pharmacologie strategies. J Clin Psychiatry 1984;45:29-38.
  • Onken LS, Blaine JD, Boren JJ, eds. Integrating behavioural therapies with medications in the treatment of drug dependence, vol. 150. NIDA Research Monograph Series. Rockville, MD: US Department of Health and Human Services, 1995.
  • Callahan E, Rawson R, McCleave B, Arias R, GlazerM, Liberman R. The treatment of heroin addiction: naltrexone alone and with behaviour therapy. Int J Addict 1980;15:795-807.
  • Rawson R, Glazer M, Callahan E, Liberman R. Naltrexone and behaviour therapy for heroin addiction, vol. 25. In: Krasnegor N, ed. Behavioural analysis and treatment of substance abuse. NIDA research monograph series. Rockville, MD: National Institute on Drug Abuse, 1979:26-43.
  • Anton R, Hogan I, Jalali B, Riordan C, Kleber H. Multiple family therapy and naltrexone in the treatment of opiate dependence. Drug Alcohol Depend 1981;8:157-68.
  • Callahan E, Rawson R, Glazer M, McCleave B, Arias R. Comparison of two naltrexone treatment programs: naltrexone alone versus naltrexone plus behaviour therapy, vol. 9. In: Julius D, Renault P, eds. Narcotic antagonists: naltrexone. NIDA research monograph series. Rockville, MD: National Institute on Drug Abuse, 1976:150-7.
  • Mattick RP, Hall W. Are detoxification programmes effective? Lancet 1996;347:97-100.
  • Senft RA. Experience with clonidine-naltrexone for rapid opiate detoxification. J Subst Abuse Treat 1991;8:257-9.
  • Vining E, Kosten TR, Kleber HD. Clinical utility of rapid clonidine-naltrexone detoxification for opioid abusers. Br J Addict 1988;83:567-75.
  • Charney DS, Heninger GR, Kleber HD. The combined use of clonidine and naltrexone as a rapid, safe and effective treatment of abrupt withdrawal from Methadone. Am J Psychiatry 1986; 143:831-7.
  • Brewer C, Rezae H, Bailey C. Opioid withdrawal and naltrexone induction in 48-72 hours with minimal drop-out, using a modification of the naltrexone-clonidine technique. Br J Psychiatry 1988;153: 340-3.
  • Kleber HD, Topazian M, Gaspari J, Riordan CE, Kosten T. Clonidine and naltrexone in the outpatient treatment of heroin withdrawal. Am J Drug Alcohol Abuse 1987;13:1-17.
  • Azatian A, Papiasvilli A, Joseph H. A study of the use of clonidine and naltrexone in the treatment of opioid addiction in the former USSR. J Addict Dis 1994;13:35-52.
  • O'Connor PG, Carroll KM, Shi JM, Schottenfeld RS, Kosten TR, Rounsaville BJ. Three methods of opioid detoxification in a primary care setting: a randomized trial. Ann Intern Med 1997;127:526-30.
  • Loimer N, Hofmann P, Chaudhry H. Ultrashort noninvasive opiate detoxification (letter). Am J Psychiatry 1993;150:839.
  • Loimer N, Lenz K, Schmid R, Presslich O. Technique for greatly shortening the transition from methadone to naltrexone maintenance of patients addicted to opiates. Am J Psychiatry 1991;148:933-5.
  • Legarda JJ, Gossop M. A 24-h inpatient detoxification treatment for heroin addicts: a preliminary investigation. Drug Alcohol Depend 1994;35:91-3.
  • Tretter F, Burkhardt D, Bussello-Spieth B, Reiss J, Walcher S, Büchele W. Clinical experience with antagonist-induced opiate withdrawal under anaesthesia. Addiction 1998;93:269-75.
  • Gossop M, Strang J. Rapid anaesthetic-antagonist detoxification of heroin addicts: what origins, evidence base and clinical justification? Br J Intens Care 1997;7:66-9.
  • Simon D. Rapid opioid detoxification using opioid antagonists: history, theory and the state of the art. J Addict Dis 1997;16:103-22.
  • Brewer C, Gooberman L, Kasvikis Y et al. Rapid opiate detoxification and naltrexone induction under general anaesthesia and assisted ventilation: experiences with 510 patients in four different centres. Boll Farmacodipend l'Alcool 1997;20:29-33.
  • Rabinowitz J. Treatment outcome study of CITA method in Australia. Israel: State University of New York at Stony Brook and Bar Ilan University, Israel, 1997.
  • Cuccia A, Bertschy G, MonnatM, Spagnoli J. Ultrarapid opiate detoxification: a clinical investigation. Eur Psychiatry 1996;2:171s.
  • Seoane A, Carrasco G, Cabre L, et al. Efficacy and safety of two new methods of rapid intravenous detoxification in heroin addicts previously treated without success. Br J Psychiatry 1997;171:340-5.
  • O'Connor PG, Kosten TR. Rapid and ultrarapid opiate detoxification techniques. JAMA 1998;279: 229-34.
  • Ward J, Mattick R, Hall W. Key issues in methadone maintenance treatment. Kensington: University of New South Wales Press, 1992.
  • Miotto K, McCann M, Rawson R, Frosch D, Ling W. Overdose, suicide attempts and death among a cohort of naltrexone-treated opioid addicts. Drug Alcohol Depend 1997;45:131-4.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.